Wedbush Remains a Buy on Oric Pharmaceuticals (ORIC)
In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a ...
Uber removed from ‘Best Idea List’ at Wedbush
Wedbush analysts removed Uber (UBER) from the firm’s “Best Idea List” but maintains an Outperform rating on the name with an $86 price target ...